Chongqing Beibei Manufacturing Site
Porton's formulation factory is a cGMP-compliant pilot and commercial production.
No.1, Gaobao Road, Beibei District, Chongqing
52,000m2Area
The factory features advanced design and equipment, utilizing state-of-the-art instruments and pharmaceutical machinery to enhance production efficiency and quality control levels.
5Production Lines
We encompass dosage forms such as tablets, capsules, injectables, patches, and creams, offering customized manufacturing services throughout the entire lifecycle of pharmaceuticals.
260+Employees
Our team has extensive project experience and follows Porton's standards.
Capabilities
Drug Product Capability
Tablet
- IR
- MR
- Double-Tablet
Capsule
- IR
- MR
- Micro-pellet Filler
Injectable
- Ampoule
- Vials for Powder & Liquid
Semisolid
- Cream
- Ointment
- Gel Paste
- Gel Patch
Maximum Annual Output Capacity
- 1B doses
- 60 M doses (HP)
- 200 M doses
- 60 M doses (HP)
- Ampoule: 30 M units
- Small Volume lnjections: 25 M units
- Lyophilized Powder Injections: 3.3 M units
- Cream/Ointment/Gel Paste: 16 MM tubes
- Gel Patch: 35 M tubes
Facilities
Tablets & Capsules
Tablets & Capsules(HP)
Injectable
Semisolid
Tablets & Capsules
The two solid preparation workshops have the production capacity for tablets and capsules, with a planned annual production capacity of 2 billion tablets or granules. These workshops possess various process capabilities, including immediate release, sustained release, enteric-coated, and solid dispersion products. Additionally, they have reserved space for granules and dry suspension process units. They have achieved a batch span ranging from hundreds of grams to hundreds of kilograms, covering the entire life cycle of drugs from clinical samples to large-scale commercialization.
Tablets & Capsules(HP)
High Potency OSD workshop The site has built a dedicated high potency oral solid dosage (OSD) workshop with an annual capacity of 100 million tablets. Advanced technologies such as a negative pressure isolation system, αβ split butterfly valve, push-push filter, and continuous bag system are utilized to meet the production demands of OEB 4 and OEB 5 high-activity tablets and capsules. These technologies ensure an industry-leading level of isolation, employee occupational health, environmental friendliness, and GMP compliance.
Injectable
The vial injection production line has a planned annual capacity of 3 million for powder needles and 25 million for water needles. The full isolator filling technology platform is suitable for non-terminal sterilization processes, is compatible with both water needle and freeze-dried powder needle dosage forms, and can meet the production requirements of various batches and processes.
Semisolid
...
One Porton One Quality
Compliance standards, Continuous improvement, Customer oriented
Quality management runs throughout the entire process of the drug life cycle. The quality management system of the drug product site is built in accordance with international standards and continues to adhere to the quality concept of 'more well-established system, more controllable quality.' This ensures that the GMP activities of the drug product site meet the requirements of international quality management systems and market drug regulatory agencies, including those of China, the European Union, FDA, and other mainstream regulations.
Case Studies
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development
Agile and Fast：Enabling Rapid Market Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months
News
MoreNews2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
More
News2024-12-19
Porton Newsletter | Q4 2024 Recap
More
News2024-12-06
Porton Recognized as an Exemplary Case for Sustainable Development
More
News2024-12-06
Porton is thrilled to announce the launch of its newly redesigned official website
More
News2024-10-14
Driving innovation and excellence in the CDMO industry, Porton at 2024 CPHI Europe
More
News2024-10-01
Porton Newsletter | Q3 2024 Recap
More
